Kanabo Group PLC Director/PDMR Dealing (7843C)
25 Febrero 2022 - 1:01AM
UK Regulatory
TIDMKNB
RNS Number : 7843C
Kanabo Group PLC
25 February 2022
Kanabo Group Plc
("Kanabo" or the "Company")
Director/PDMR Dealing
Kanabo Group Plc (LSE:KNB), the pan-European medical cannabis
Company focussing on the development and distribution of
cannabis-derived products for medical patients and wellness CBD
consumers, announces Daniel Poulter, Non- Executive Director, has
purchased 55,000 ordinary shares at a price of 7.4p.
Avihu Tamir, CEO, commented: "Since joining Kanabo in June 2021
Dan has become an invaluable member of the board. I welcome his
most recent show of support by acquiring shares in the market. With
the recent acquisition of the GP Service, and completion of an
oversubscribed fundraise, Kanabo has approximately GBP6.4m and is
well positioned to implement its growth strategy".
The notification set out below is provided in accordance with
the requirements of Article 19 of the UK Market Abuse
Regulation.
For further information, please visit
http://www.kanabogroup.com/ or contact the following:
Kanabo Group Plc Via Vox Markets
Avihu Tamir, CEO
Peterhouse Capital Ltd (Financial Tel: +44 (0)20 7469 0930
Adviser)
Eran Zucker / Lauren Riley
Peterhouse Capital Ltd (Corporate Tel: +44 (0)20 7469 0930
Broker)
Lucy Williams / Charles Goodfellow
Vox Markets (Investor Relations) KanaboGroup@voxmarkets.co.uk
Kat Perez kperez@voxmarkets.co.uk
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name
Daniel Poulter
--------------------------------------- ---------------------------------------
2 Reason for the notification
--------------------------------------------------------------------------------
a) Position/status Non-Executive Director
--------------------------------------- ---------------------------------------
b) Initial notification Initial notification
/Amendment
--------------------------------------- ---------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer, or auction monitor
--------------------------------------------------------------------------------
a) Name Kanabo Group Plc
--------------------------------------- ---------------------------------------
b) LEI 213800XPJFSNWJIYKN52
--------------------------------------- ---------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
--------------------------------------------------------------------------------
a) Description of the Ordinary Shares of 2.5 pence each
financial instrument, in Kanabo Group Plc
type of instrument
Identification code GB00BYQCS703
b) Nature of the transaction Purchase of shares
--------------------------------------- ---------------------------------------
c) Price(s) and volume(s)
----------------- -----------------
Price(s) Volume(s)
----------------- -----------------
7.4p 55,000
----------------- -----------------
d) Aggregated information
- Aggregated volume 55,000
- Price GBP4,053
e) Date of the transaction 24/02/2022
--------------------------------------- ---------------------------------------
f) Place of the transaction Standard List of the Main Market
--------------------------------------- ---------------------------------------
Following the share purchase, Mr Poulter's beneficial interests
in the capital of the Company is 0.013%.
About Kanabo Group Plc
Kanabo Group Plc is creating a new standard in the medical
cannabis industry to improve the well-being of millions of people
around the world by providing a better alternative to the smoking
of medicinal cannabis flowers. Kanabo, which was the first
medicinal cannabis company to IPO on London Stock Exchange, has a
focus on the distribution of cannabis-derived products for medical
patients and non-THC products for CBD consumers. It has conducted
extensive Research & Development to produce high-quality
cannabis extract formulas, innovative medical-grade vaporizers, and
various non-smoking consumption solutions. Kanabo sells a range of
medical cannabis products and wellness CBD products in the Primary
Markets, including its VapePod, which delivers a metered dose with
every inhalation.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHPPUQPPUPPGBC
(END) Dow Jones Newswires
February 25, 2022 02:01 ET (07:01 GMT)
Kanabo (LSE:KNB)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Kanabo (LSE:KNB)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
